Risk Of Developing Liver Cancer After HCV Treatment

Monday, March 26, 2012

CROI 2012: HIV/HCV co-infected people see improved HCV cure rates with Victrelis

All study participants were given pegylated interferon + ribavirin for the first 4 weeks of treatment. About 2/3 had Victrelis added to their regimen for the next 44 weeks while the other third continued on pegylated interferon + ribavirin alone. Nearly all participants were on a boosted protease inhibitor HIV regimen.
The average age of the participants was 44, and 31% were women. Most people had high HCV viral loads, while 5% had cirrhosis. Nearly 65% had HCV genotype 1a while the others had 1b. CD4 counts averaged 580 and all had undetectable HIV viral load.

The following chart describes 12-week post-treatment undetectable HCV viral loads (B/PR = Victrelis + pegylated interferon + ribavirin):

Undetectable HCVB/PRPR
4 wks4.7%8.8%
8 wks37.5%14.7%
12 wks56.5%25.0%
24 wks70.5%34.4%
48 wks65.6%29.4%
12 wks post60.7%26.5%

The following details should be noted about this study:
  • Two people saw their HCV return after being undetectable at week 48.
  • HIV viral loads became detectable in 3 people taking Victrelis.
  • CD4 counts tended to decrease in everyone; however, the CD4% did not change.
  • High rates of side effects were seen in the Victrelis group, including bad taste (28%), vomiting (28%), diarrhea (28%), anemia (41%), fever (36%), headache (23%), appetite loss (34%) and fatigue (36%). Serious anemia occurred in 5% and low neutrophil counts (27%).
A larger study will start enrolling by the end of the year.

For other coverage on this topic:
AIDSmeds.com
HIVandHepatitis
AIDSmap.com

No comments:

Post a Comment